Peer-reviewed veterinary case report
Trilostane treatment improves symptoms and survival in cats
By Mellett Keith, A M et al.·Published in Journal of veterinary internal medicine·2013·School of Veterinary Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Trilostane therapy for treatment of spontaneous hyperadrenocorticism in cats: 15 cases (2004-2012).
- Species:
- cat
Plain-English summary
A group of 15 cats with hyperadrenocorticism (HAC), a condition that can cause symptoms like increased thirst and urination, were treated with a medication called trilostane. Most of the cats showed improvement in their symptoms and hormone levels after starting the treatment. For those with diabetes, insulin needs decreased significantly within two months. The average survival time for these cats was about 617 days, and while some experienced complications, trilostane was generally well-tolerated and helped manage their condition effectively.
People also search for: cat hyperadrenocorticism treatment · trilostane for cats · diabetes in cats symptoms · cat weight loss causes
Abstract
BACKGROUND: Medical treatment with trilostane improves clinical signs, causes unclear insulin requirement changes, and variable survival times in cats. OBJECTIVES/HYPOTHESIS: To characterize the long-term efficacy of trilostane in treating cats with hyperadrenocorticism (HAC). ANIMALS: Fifteen client-owned cats with spontaneous HAC. METHODS: Multicenter descriptive retrospective study with a search performed on all medical records for cats diagnosed with spontaneous HAC. RESULTS: Clinical signs (13 of 15 cats) and ACTH stimulation testing results (13 of 15) improved with trilostane therapy. Diabetes mellitus was reported in 9/15 cases. Insulin requirements decreased by 36% within 2 months in 6/9 diabetic cats. Median survival time was 617 days for all cats (range 80-1,278 days). Complications included weight loss, urinary tract infections, chronic kidney disease, seizures, and recurrent pancreatitis. Hypocortisolemia was documented in 1 case. Cause of death occurred as a result of nonadrenal or nondiabetic illnesses (renal failure, seizures [caused by hypoglycemia or unknown]), or lymphoma. CONCLUSIONS AND CLINICAL IMPORTANCE: Trilostane ameliorates clinical signs of HAC in cats, is tolerated well in the long term, and can lead to improved regulation of diabetes.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24011349/